IDEAS home Printed from https://ideas.repec.org/a/eee/hepoli/v106y2012i3p211-224.html
   My bibliography  Save this article

Policies to promote use of generic medicines in low and middle income countries: A review of published literature, 2000–2010

Author

Listed:
  • Kaplan, Warren A.
  • Ritz, Lindsay Sarah
  • Vitello, Marie
  • Wirtz, Veronika J.

Abstract

Review the literature on the impact of policies designed to enhance uptake of generic medicines in low and middle income countries (LMICs).

Suggested Citation

  • Kaplan, Warren A. & Ritz, Lindsay Sarah & Vitello, Marie & Wirtz, Veronika J., 2012. "Policies to promote use of generic medicines in low and middle income countries: A review of published literature, 2000–2010," Health Policy, Elsevier, vol. 106(3), pages 211-224.
  • Handle: RePEc:eee:hepoli:v:106:y:2012:i:3:p:211-224
    DOI: 10.1016/j.healthpol.2012.04.015
    as

    Download full text from publisher

    File URL: http://www.sciencedirect.com/science/article/pii/S0168851012001327
    Download Restriction: Full text for ScienceDirect subscribers only

    File URL: https://libkey.io/10.1016/j.healthpol.2012.04.015?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. John Rizzo & Richard Zeckhauser, 2009. "Generic script share and the price of brand-name drugs: the role of consumer choice," International Journal of Health Economics and Management, Springer, vol. 9(3), pages 291-316, September.
    2. Faden, Laura & Vialle-Valentin, Catherine & Ross-Degnan, Dennis & Wagner, Anita, 2011. "Active pharmaceutical management strategies of health insurance systems to improve cost-effective use of medicines in low- and middle-income countries: A systematic review of current evidence," Health Policy, Elsevier, vol. 100(2), pages 134-143.
    3. Maïga, Fatoumata Ina & Haddad, Slim & Fournier, Pierre & Gauvin, Lise, 2003. "Public and private sector responses to essential drugs policies:: a multilevel analysis of drug prescription and selling practices in Mali," Social Science & Medicine, Elsevier, vol. 57(5), pages 937-948, September.
    4. Lim, David & Emery, Jon & Lewis, Janice & Sunderland, V Bruce, 2009. "A systematic review of the literature comparing the practices of dispensing and non-dispensing doctors," Health Policy, Elsevier, vol. 92(1), pages 1-9, September.
    5. Panos Kanavos & Joan Costa-Font & Elizabeth Seeley, 2008. "Competition in off-patent drug markets: Issues, regulation and evidence [‘Substitution laws, insurance coverage, and generic drug use’]," Economic Policy, CEPR, CESifo, Sciences Po;CES;MSH, vol. 23(55), pages 500-544.
    6. Konigbauer, Ingrid, 2007. "Advertising and generic market entry," Journal of Health Economics, Elsevier, vol. 26(2), pages 286-305, March.
    7. Akaleephan, Chutima & Wibulpolprasert, Suwit & Sakulbumrungsil, Rungpetch & Luangruangrong, Paithip & Jitraknathee, Anchalee & Aeksaengsri, Achara & Udomaksorn, Siripa & Tangcharoensathien, Viroj & Ta, 2009. "Extension of market exclusivity and its impact on the accessibility to essential medicines, and drug expense in Thailand: Analysis of the effect of TRIPs-Plus proposal," Health Policy, Elsevier, vol. 91(2), pages 174-182, July.
    8. Faden, Laura & Vialle-Valentin, Catherine & Ross-Degnan, Dennis & Wagner, Anita, 2011. "Active pharmaceutical management strategies of health insurance systems to improve cost-effective use of medicines in low- and middle-income countries: A systematic review of current evidence," Health Policy, Elsevier, vol. 100(2-3), pages 134-143, May.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Marlène Guillon & Josselin Thuilliez, 2015. "HIV and Rational risky behaviors: a systematic review of published empirical literature (1990-2013)," Post-Print halshs-01222571, HAL.
    2. Sabine Vogler & Valérie Paris & Alessandra Ferrario & Veronika J. Wirtz & Kees Joncheere & Peter Schneider & Hanne Bak Pedersen & Guillaume Dedet & Zaheer-Ud-Din Babar, 2017. "How Can Pricing and Reimbursement Policies Improve Affordable Access to Medicines? Lessons Learned from European Countries," Applied Health Economics and Health Policy, Springer, vol. 15(3), pages 307-321, June.
    3. Warren A Kaplan & Veronika J Wirtz & Peter Stephens, 2013. "The Market Dynamics of Generic Medicines in the Private Sector of 19 Low and Middle Income Countries between 2001 and 2011: A Descriptive Time Series Analysis," PLOS ONE, Public Library of Science, vol. 8(9), pages 1-11, September.
    4. Katrina Perehudoff & Ivan Demchenko & Nikita V. Alexandrov & David Brutsaert & Angela Ackon & Carlos E. Durán & Faris El-Dahiyat & Firdaus Hafidz & Rezwan Haque & Rabia Hussain & Roderick Salenga & Fa, 2020. "Essential Medicines in Universal Health Coverage: A Scoping Review of Public Health Law Interventions and How They Are Measured in Five Middle-Income Countries," IJERPH, MDPI, vol. 17(24), pages 1-30, December.
    5. Omar Galárraga & Veronika J Wirtz & Yared Santa-Ana-Tellez & Eline L Korenromp, 2013. "Financing HIV Programming: How Much Should Low- And Middle-Income Countries and their Donors Pay?," PLOS ONE, Public Library of Science, vol. 8(7), pages 1-11, July.
    6. Mingyue Zhao & Lingyi Zhang & Zhitong Feng & Yu Fang, 2021. "Physicians’ Knowledge, Attitude and Practice of Generic Substitution in China: A Cross-Sectional Online Survey," IJERPH, MDPI, vol. 18(15), pages 1-13, July.
    7. Dai, Rong & Watal, Jayashree, 2021. "Product patents and access to innovative medicines," Social Science & Medicine, Elsevier, vol. 291(C).
    8. repec:hal:wpaper:halshs-01222571 is not listed on IDEAS
    9. Lins Ferreira, Vinicius & Pereira da Veiga, Cássia Rita & Kudlawicz-Franco, Claudineia & Scalercio, Priscila & Ramires, Yohanna & Pontarolo, Roberto & Carvalho, Denise Maria W. & da Veiga, Claudimar , 2017. "Generic drugs in times of economic crisis: Are there changes in consumer purchase intention?," Journal of Retailing and Consumer Services, Elsevier, vol. 37(C), pages 1-7.
    10. Yanqi Wu & Jie Chen & Hui Fang & Yuehua Wan, 2020. "Intimate Partner Violence: A Bibliometric Review of Literature," IJERPH, MDPI, vol. 17(15), pages 1-17, August.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Katrina Perehudoff & Ivan Demchenko & Nikita V. Alexandrov & David Brutsaert & Angela Ackon & Carlos E. Durán & Faris El-Dahiyat & Firdaus Hafidz & Rezwan Haque & Rabia Hussain & Roderick Salenga & Fa, 2020. "Essential Medicines in Universal Health Coverage: A Scoping Review of Public Health Law Interventions and How They Are Measured in Five Middle-Income Countries," IJERPH, MDPI, vol. 17(24), pages 1-30, December.
    2. Tello, Juan E. & Barbazza, Erica & Waddell, Kerry, 2020. "Review of 128 quality of care mechanisms: A framework and mapping for health system stewards," Health Policy, Elsevier, vol. 124(1), pages 12-24.
    3. Cao, Zong-Hong & Zhou, Yong-Wu & Zhao, Ju & Li, Chang-Wen, 2015. "Entry mode selection and its impact on an incumbent supply chain coordination," Journal of Retailing and Consumer Services, Elsevier, vol. 26(C), pages 1-13.
    4. Bate, Roger & Jin, Ginger Zhe & Mathur, Aparna, 2011. "Does price reveal poor-quality drugs? Evidence from 17 countries," Journal of Health Economics, Elsevier, vol. 30(6), pages 1150-1163.
    5. Bence Kovács & Miklós Darida & Judit Simon, 2021. "Drugs Becoming Generics—The Impact of Genericization on the Market Performance of Antihypertensive Active Pharmaceutical Ingredients," IJERPH, MDPI, vol. 18(18), pages 1-20, September.
    6. Pierre Dubois & Morten Sæthre, 2020. "On the Effect of Parallel Trade on Manufacturers' and Retailers' Profits in the Pharmaceutical Sector," Econometrica, Econometric Society, vol. 88(6), pages 2503-2545, November.
    7. Brekke, Kurt R. & Holmas, Tor Helge & Straume, Odd Rune, 2011. "Reference pricing, competition, and pharmaceutical expenditures: Theory and evidence from a natural experiment," Journal of Public Economics, Elsevier, vol. 95(7), pages 624-638.
    8. Takizawa, Osamu & Urushihara, Hisashi & Tanaka, Shiro & Kawakami, Koji, 2015. "Price difference as a predictor of the selection between brand name and generic statins in Japan," Health Policy, Elsevier, vol. 119(5), pages 612-619.
    9. Jacqmin, Julien, 2014. "The Emergence of For-Profit Higher Education Institutions," MPRA Paper 59299, University Library of Munich, Germany.
    10. Fernando Antoñanzas & Carmelo Juárez-Castelló & Roberto Rodríguez-Ibeas, 2011. "Innovation, loyalty and generic competition in pharmaceutical markets," SERIEs: Journal of the Spanish Economic Association, Springer;Spanish Economic Association, vol. 2(1), pages 75-95, March.
    11. Brekke, Kurt R. & Kuhn, Michael, 2006. "Direct to consumer advertising in pharmaceutical markets," Journal of Health Economics, Elsevier, vol. 25(1), pages 102-130, January.
    12. Ivan Moreno-Torres, 2011. "What if there was a stronger pharmaceutical price competition in Spain? When regulation has a similar effect to collusion," Working Papers XREAP2011-02, Xarxa de Referència en Economia Aplicada (XREAP), revised May 2011.
    13. Olivia Bodnar & Hugh Gravelle & Nils Gutacker & Annika Herr, 2024. "Financial incentives and prescribing behavior in primary care," Health Economics, John Wiley & Sons, Ltd., vol. 33(4), pages 696-713, April.
    14. Ricardo Arcaro & Cássia Rita Pereira da Veiga & Wesley Vieira da Silva & Claudimar Pereira da Veiga, 2021. "Attitude and Purchase Intention to Generic Drugs," IJERPH, MDPI, vol. 18(9), pages 1-16, April.
    15. Granlund, David & Rudholm, Niklas, 2008. "Consumer Loyalty in the Swedish Pharmaceuticals Market," HUI Working Papers 17, HUI Research.
    16. Kwon, Hye-Young & Hong, Ji-Min & Godman, Brian & Yang, Bong-Min, 2013. "Price cuts and drug spending in South Korea: The case of antihyperlipidemic agents," Health Policy, Elsevier, vol. 112(3), pages 217-226.
    17. Katharina Elisabeth Fischer & Tom Stargardt, 2016. "The diffusion of generics after patent expiry in Germany," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 17(8), pages 1027-1040, November.
    18. Brekke, Kurt R. & Grasdal, Astrid L. & Holms, Tor Helge, 2009. "Regulation and pricing of pharmaceuticals: Reference pricing or price cap regulation?," European Economic Review, Elsevier, vol. 53(2), pages 170-185, February.
    19. Matthias Stoll & Christian Kollan & Frank Bergmann & Johannes Bogner & Gerd Faetkenheuer & Carlos Fritzsche & Kirsten Hoeper & Heinz-August Horst & Jan van Lunzen & Andreas Plettenberg & Stefan Reuter, 2011. "Calculation of Direct Antiretroviral Treatment Costs and Potential Cost Savings by Using Generics in the German HIV ClinSurv Cohort," PLOS ONE, Public Library of Science, vol. 6(9), pages 1-12, September.
    20. Kanavos, Panos G. & Vandoros, Sotiris, 2011. "Determinants of branded prescription medicine prices in OECD countries," Health Economics, Policy and Law, Cambridge University Press, vol. 6(3), pages 337-367, July.

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:eee:hepoli:v:106:y:2012:i:3:p:211-224. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Catherine Liu or the person in charge (email available below). General contact details of provider: http://www.elsevier.com/locate/healthpol .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.